在心房的速率控制,通道阻塞剂与β-阻塞剂
Tim Koldenhof1,2, Isabelle C Van Gelder2, Harry Jgm Crijns3
1Department of Cardiology, Martini Hospital, Groningen, The Netherlands.
Heart (British Cardiac Society)
|July 11, 2023
概括
非二皮里丁类通道阻塞剂和β阻塞剂在心房动 (AF) 中有效控制心率. 在AF患者中,通道阻塞剂与贝塔阻塞剂相比,在鼻节律期间与较少的胸肌梗塞有关.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心房动 (AF) 是一种常见的心律失常,需要控制心率.
- 非二皮里丁通道阻塞剂和β阻塞剂经常用于AF的速率控制.
研究的目的:
- 在非永久性AF患者中,比较非二皮里丁通道阻塞剂与β阻塞剂对心率的影响.
- 评估与这些药物治疗的患者在鼻节律期间发生的胸肌梗塞的发生率.
主要方法:
- 来自AFFIRM试验的数据分析 (对心脏动患者的节律控制和节律控制的比较).
- 在随机分配到节奏控制的患者中,AF期间的心率和鼻节律的比较.
- 用于调整基线特征的多变量逻辑回归.
主要成果:
- 在AF期间,这两类药物都在92%的患者中实现了目标心率 (<110bpm).
- 鼻节律期间的胸心发生在17%的通道阻塞剂使用者身上,而32%的β阻塞剂使用者身上 (p<0.001).
- 通道阻塞剂与在鼻节律 (OR 0.41) 期间降低胸风险有关.
结论:
- 与非永久性AF患者中的β阻塞剂相比,非二皮里丁通道阻塞剂在鼻节律期间与较少的胸肌梗塞有关.
- 这两种药物类别都有效控制AF的速率.
相关概念视频
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
880
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
880
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
777
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
777
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
571
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
571
Antihypertensive Drugs: Action of Calcium Channel Blockers
579
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
579
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.1K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.5K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.5K


